Cue Biopharma, Inc. (CUE)
Health Care · T cell immunotherapy and cellular immunomodulation · Nasdaq
Cue Biopharma engineers injectable biologics that selectively modulate disease-specific T cells to restore immune tolerance in autoimmune diseases and activate anti-tumor immunity in cancer.
What Cue Biopharma, Inc. does
Cue Biopharma is a clinical-stage biopharmaceutical company developing injectable therapeutics engineered to selectively engage and modulate disease-specific T cells. The company's novel Immuno-STAT platform is designed to target autoimmune, inflammatory, and oncology diseases by promoting immune tolerance and selectively activating tumor-specific T cells, with lead programs including CUE-401 for autoimmune conditions and CUE-501 licensed to Boehringer Ingelheim for B cell depletion.
Themes: ["T cell engineering / immunomodulation","autoimmune disease treatment","immune tolerance / Treg induction","cell-mediated depletion","oncology / tumor-specific T cells"]
Fundamentals
- Price$36.78 as of 2026-07-10 close
- Market cap$154M as of 2026-07-13
- 1-year return+54.0% as of 2026-07-10 close
- Net margin-59.6% as of 2026-07-13
- ROE-98.3% as of 2026-07-13
- Debt / equity0.00 as of 2026-07-13
- Revenue growth (YoY)+309.6% as of 2026-07-13
- Revenue CAGR (3y)+180.5% SEC XBRL
- Beta2.50 as of 2026-07-13
Key risks (from latest filing)
["Clinical development risk: CUE-401 is preclinical with Phase 1 trial expected in H2 2026; failure to demonstrate safety, efficacy, or obtain regulatory approval would prevent commercialization","Funding and going concern risk: Company is unprofitable with high burn rate; stated ability to continue as a going concern depends on obtaining additional funding and achieving operational milestones","Partnership/licensing dependency risk: Key programs (CUE-501, CUE-101, CUE-102) are licensed to third parties; company's success depends on partners' execution and decisions"]
Competitors & peers
- Juno Therapeutics
- Kymriah (Novartis CAR-T unit)
- Fate Therapeutics
- Lyell Immunopharma
- Arcus Biosciences
- Surface Oncology
Fundamentals: Finnhub, as of 2026-07-13. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-10.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date.